comparemela.com

Latest Breaking News On - Shiran zimri - Page 5 : comparemela.com

NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesUnited kingdomShiran zimriPrnewswire neurosense therapeutics ltdDrug administrationWorld orphan drug congressNeurosense therapeutics ltdEuropean medicines agencySense therapeuticsMassachusetts general hospitalScientific programsOrphan drug designationNeuron derived exosomesHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesUnited kingdomCity ofFerenc tracikNedira salzman frenkelShiran zimriCompany head of scientific programPrnewswire neurosense therapeutics ltdDrug development summitNeurosense therapeutics ltdEuropean network to cureEuropean medicines agencyBusiness developmentCombination therapyTarget complexitySense therapeutics

NeuroSense Therapeutics, Ltd Announces the Presentation of Phase IIa Study Results at Four International Conferences

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomComunidad autonoma de catalunaShiran zimriResearch symposiumInternational conference on alzheimer parkinsonPrnewswire neurosense therapeutics ltdIsraeli neurological association annual meetingNeurosense therapeutics ltdSense therapeuticsInternational conferenceIsraeli neurological association annualScientific programs

vimarsana © 2020. All Rights Reserved.